Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...

Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...

She joins a team of experts at ON Partners, including partners Nina McMaster and Suzanne Zebedee, Ph.D., both recognized for ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...